Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.

Phase 2

Completed

• Conditions: Sarcoma, Kaposi; HIV Infections

• Registration Number: NCT00002167
• Lead Sponsor: Clinical Solutions

Brief Summary

To determine the objective tumor response and remission rate of AIDS-related Kaposi's sarcomas (KS) following a single dose of tin ethyl etiopurpurin (SnET2) followed by photodynamic therapy (PDT). To determine the systemic and local toxicity, and morbidity safety profile of SnET2-PDT.

Detailed Description

All patients receive a single dose of SnET2 and are randomized to receive either PDT light treatment or no light treatment (control group). Patients are assessed prior to and at 4, 12 and 24 weeks following treatment, and are followed for 7 months.

Study Timeline

• Status Verified: 1999-04
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 78

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (6)

Univ of Southern California / Los Angeles; 🇺🇸 Los Angeles, California, United States

Cedars Sinai Med Ctr; 🇺🇸 Los Angeles, California, United States

Thompson Cancer Survival Ctr; 🇺🇸 Knoxville, Tennessee, United States

Univ of California / San Francisco / Dermatology; 🇺🇸 San Francisco, California, United States

Health One - Rocky Mountain Cancer Ctr; 🇺🇸 Denver, Colorado, United States

Buffalo Gen Hosp / PDT Ctr; 🇺🇸 Buffalo, New York, United States